271 related articles for article (PubMed ID: 31711450)
1. Longitudinal profiling of gut microbiome among tuberculosis patients under anti-tuberculosis treatment in China: protocol of a prospective cohort study.
Shi W; Hu Y; Zheng X; Ning Z; Wu M; Xia F; Prast-Nielsen S; Hu YOO; Xu B
BMC Pulm Med; 2019 Nov; 19(1):211. PubMed ID: 31711450
[TBL] [Abstract][Full Text] [Related]
2. Gut Mycobiota Dysbiosis in Pulmonary Tuberculosis Patients Undergoing Anti-Tuberculosis Treatment.
Cao D; Liu W; Lyu N; Li B; Song W; Yang Y; Zhu J; Zhang Z; Zhu B
Microbiol Spectr; 2021 Dec; 9(3):e0061521. PubMed ID: 34908436
[TBL] [Abstract][Full Text] [Related]
3. Gut microbiota associated with pulmonary tuberculosis and dysbiosis caused by anti-tuberculosis drugs.
Hu Y; Yang Q; Liu B; Dong J; Sun L; Zhu Y; Su H; Yang J; Yang F; Chen X; Jin Q
J Infect; 2019 Apr; 78(4):317-322. PubMed ID: 30107196
[TBL] [Abstract][Full Text] [Related]
4. Alterations of gut microbiota in patients with active pulmonary tuberculosis in China: a pilot study.
Shi W; Hu Y; Ning Z; Xia F; Wu M; Hu YOO; Chen C; Prast-Nielsen S; Xu B
Int J Infect Dis; 2021 Oct; 111():313-321. PubMed ID: 34481968
[TBL] [Abstract][Full Text] [Related]
5. Impact of alcohol consumption on tuberculosis treatment outcomes: a prospective longitudinal cohort study protocol.
Myers B; Bouton TC; Ragan EJ; White LF; McIlleron H; Theron D; Parry CDH; Horsburgh CR; Warren RM; Jacobson KR
BMC Infect Dis; 2018 Sep; 18(1):488. PubMed ID: 30268101
[TBL] [Abstract][Full Text] [Related]
6. Chinese herbal medicine bi min fang for allergic rhinitis: protocol for a double-blind, double-dummy, randomized controlled trial.
Luo Q; Zhou S; Li X; Chen Q; Lin W; Lu L; Li H; Chen C; Chen W; Li Y
Trials; 2019 Jan; 20(1):66. PubMed ID: 30658660
[TBL] [Abstract][Full Text] [Related]
7. The Dysbiosis Triggered by First-Line Tuberculosis Antibiotics Fails to Reduce Their Bioavailability.
Namasivayam S; Zimmerman M; Oland S; Wang H; Mittereder LR; Dartois V; Sher A
mBio; 2023 Apr; 14(2):e0035323. PubMed ID: 36877010
[TBL] [Abstract][Full Text] [Related]
8. Exploring the role of Microbiome in Susceptibility, Treatment Response and Outcome among Tuberculosis Patients from Pakistan: study protocol for a prospective cohort study (Micro-STOP).
Shahzad M; Andrews SC; Ul-Haq Z
BMJ Open; 2022 Jun; 12(6):e058463. PubMed ID: 35672071
[TBL] [Abstract][Full Text] [Related]
9. The host microbiome and impact of tuberculosis chemotherapy.
O'Toole RF; Gautam SS
Tuberculosis (Edinb); 2018 Dec; 113():26-29. PubMed ID: 30514510
[TBL] [Abstract][Full Text] [Related]
10. Patients infected with Mycobacterium africanum versus Mycobacterium tuberculosis possess distinct intestinal microbiota.
Namasivayam S; Diarra B; Diabate S; Sarro YDS; Kone A; Kone B; Tolofoudie M; Baya B; Diakite MT; Kodio O; Cohen K; Holl J; Achenbach CJ; Chatterjee S; Murphy RL; Bishai W; Diallo S; Sher A; Maiga M
PLoS Negl Trop Dis; 2020 May; 14(5):e0008230. PubMed ID: 32401750
[TBL] [Abstract][Full Text] [Related]
11.
Meng R; Dong W; Gao J; Lu C; Zhang C; Liao Q; Chen L; Wu H; Hu J; Wei W; Jiang Z
Indian J Microbiol; 2022 Sep; 62(3):374-383. PubMed ID: 35974910
[TBL] [Abstract][Full Text] [Related]
12. Increased Th17 activation and gut microbiota diversity are associated with pembrolizumab-triggered tuberculosis.
Zhang YB; Liu SJ; Hu ZD; Zhou JX; Wang YZ; Fang B; Wong KW; Xia F
Cancer Immunol Immunother; 2020 Dec; 69(12):2665-2671. PubMed ID: 32761425
[TBL] [Abstract][Full Text] [Related]
13. Metformin-induced changes of the gut microbiota in healthy young men: results of a non-blinded, one-armed intervention study.
Bryrup T; Thomsen CW; Kern T; Allin KH; Brandslund I; Jørgensen NR; Vestergaard H; Hansen T; Hansen TH; Pedersen O; Nielsen T
Diabetologia; 2019 Jun; 62(6):1024-1035. PubMed ID: 30904939
[TBL] [Abstract][Full Text] [Related]
14. Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study.
Carvalho ACC; Amorim G; Melo MGM; Silveira AKA; Vargas PHL; Moreira ASR; Rocha MS; Souza AB; Arriaga MB; Araújo-Pereira M; Figueiredo MC; Durovni B; Lapa-E-Silva JR; Cavalcante S; Rolla VC; Sterling TR; Cordeiro-Santos M; Andrade BB; Silva EC; Kritski AL;
Front Immunol; 2021; 12():661934. PubMed ID: 34276654
[TBL] [Abstract][Full Text] [Related]
15. Correlation between Disease Severity and the Intestinal Microbiome in Mycobacterium tuberculosis-Infected Rhesus Macaques.
Namasivayam S; Kauffman KD; McCulloch JA; Yuan W; Thovarai V; Mittereder LR; Trinchieri G; Barber DL; Sher A
mBio; 2019 Jun; 10(3):. PubMed ID: 31164469
[TBL] [Abstract][Full Text] [Related]
16. [A comparative study on the difference of gut microbiota and its biomarkers between patients with pulmonary tuberculosis and healthy controls].
Lu YH; Shi WP; Hu Y; Xia F; Ning Z; Wu MY; Chen C; O Hu Y; Xu B
Zhonghua Jie He He Hu Xi Za Zhi; 2021 Nov; 44(11):939-946. PubMed ID: 34758519
[No Abstract] [Full Text] [Related]
17. The gut microbiome in tuberculosis susceptibility and treatment response: guilty or not guilty?
Eribo OA; du Plessis N; Ozturk M; Guler R; Walzl G; Chegou NN
Cell Mol Life Sci; 2020 Apr; 77(8):1497-1509. PubMed ID: 31729564
[TBL] [Abstract][Full Text] [Related]
18. Effect of seven anti-tuberculosis treatment regimens on sputum microbiome: a retrospective analysis of the HIGHRIF study 2 and PanACEA MAMS-TB clinical trials.
Musisi E; Wyness A; Eldirdiri S; Dombay E; Mtafya B; Ntinginya NE; Heinrich N; Kibiki GS; Hoelscher M; Boeree M; Aarnoutse R; Gillespie SH; Sabiiti W;
Lancet Microbe; 2023 Nov; 4(11):e913-e922. PubMed ID: 37832571
[TBL] [Abstract][Full Text] [Related]
19. Gastrointestinal microbiota composition predicts peripheral inflammatory state during treatment of human tuberculosis.
Wipperman MF; Bhattarai SK; Vorkas CK; Maringati VS; Taur Y; Mathurin L; McAulay K; Vilbrun SC; Francois D; Bean J; Walsh KF; Nathan C; Fitzgerald DW; Glickman MS; Bucci V
Nat Commun; 2021 Feb; 12(1):1141. PubMed ID: 33602926
[TBL] [Abstract][Full Text] [Related]
20. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
